scholarly journals STAT3 Decoy Oligonucleotide

2020 ◽  
Author(s):  
Keyword(s):  
Decoy Oligonucleotide ◽  
Stat3 Decoy

scholarly journals First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy

2012 ◽  
Vol 2 (8) ◽  
pp. 694-705 ◽  
Author(s):  
Malabika Sen ◽  
Sufi M. Thomas ◽  
Seungwon Kim ◽  
Joanne I. Yeh ◽  
Robert L. Ferris ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Head And Neck ◽  
Head And Neck Tumors ◽  
Human Trial ◽  
Neck Tumors ◽  
Decoy Oligonucleotide ◽  
Stat3 Decoy

scholarly journals Lack of toxicity of a STAT3 decoy oligonucleotide

2008 ◽  
Vol 63 (6) ◽  
pp. 983-995 ◽  
Author(s):  
Malabika Sen ◽  
Patricia J. Tosca ◽  
Christa Zwayer ◽  
Michael J. Ryan ◽  
Jerry D. Johnson ◽  
...  
Keyword(s):  
Decoy Oligonucleotide ◽  
Stat3 Decoy

scholarly journals STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors

PLoS ONE ◽  
2020 ◽  
Vol 15 (11) ◽  
pp. e0242264
Author(s):  
Thiruganesh Ramasamy ◽  
Xucai Chen ◽  
Bin Qin ◽  
Daniel E. Johnson ◽  
Jennifer R. Grandis ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Tumor Progression ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Clinical Translation ◽  
Data Set ◽  
Decoy Oligonucleotide ◽  
Stat3 Decoy

Signal transducer and activator of transcription-3 (STAT3) is an oncogenic transcription factor implicated in carcinogenesis, tumor progression, and drug resistance in head and neck squamous cell carcinoma (HNSCC). A decoy oligonucleotide targeting STAT3 offers a promising anti-tumor strategy, but achieving targeted tumor delivery of the decoy with systemic administration poses a significant challenge. We previously showed the potential for STAT3 decoy-loaded microbubbles, in conjunction with ultrasound targeted microbubble cavitation (UTMC), to decrease tumor growth in murine squamous cell carcinoma. As a next step towards clinical translation, we sought to determine the anti-tumor efficacy of our STAT3 decoy delivery platform against human HNSCC and the effect of higher STAT3 decoy microbubble loading on tumor cell inhibition. STAT3 decoy was loaded on cationic lipid microbubbles (STAT3-MB) or loaded on liposome-conjugated lipid microbubbles to form STAT3-loaded liposome-microbubble complexes (STAT3-LPX). UTMC treatment efficacy with these two formulations was evaluated in vitro using viability and apoptosis assays in CAL33 (human HNSCC) cells. Anti-cancer efficacy in vivo was performed in a CAL33 tumor murine xenograft model. UTMC with STAT3-MB caused significantly lower CAL33 cell viability compared to UTMC with STAT3-LPX (56.8±8.4% vs 84.5±8.8%, respectively, p<0.05). In vivo, UTMC with STAT3-MB had strong anti-tumor effects, with significantly less tumor burden and greater survival compared to that of UTMC with microbubbles loaded with a mutant control decoy and untreated control groups (p<0.05). UTMC with STAT3 decoy-loaded microbubbles significantly decreases human HNSSC tumor progression. These data set the stage for clinical translation of our microbubble platform as an imaged-guided, targeted delivery strategy for STAT3 decoy, or other nucleotide-based therapeutics, in human cancer treatment.

Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells

Blood ◽  
1998 ◽  
Vol 92 (3) ◽  
pp. 990-995 ◽  
Author(s):  
Maria Fiammetta Romano ◽  
Annalisa Lamberti ◽  
Pierfrancesco Tassone ◽  
Fiorella Alfinito ◽  
Silvia Costantini ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Consensus Sequence ◽  
Significant Proportion ◽  
Lymphocytic Leukemia ◽  
Antiapoptotic Effect ◽  
Apoptotic Effect ◽  
American Society ◽  
Induced Apoptosis ◽  
Decoy Oligonucleotide

Abstract We analyzed the effect of CD40 triggering on the fludarabine-induced apoptosis of B chronic lymphocytic leukemia (B-CLL) cells. Peripheral blood samples obtained from 15 patients were incubated with fludarabine in the absence or the presence of the anti-CD40 monoclonal antibody (MoAb) G28-5. In 12 patients a significant proportion of apoptotic cells, ranging from 22% to 38% (mean ± SE: 28.5 ± 1.6), were detected after 3 days of culture. In 9 of these samples, the addition of G28-5 reduced apoptosis by at least 30.1% and by 57.1% ± 7.8% on average (P = .0077). Because the CD40 antigen activates NF-κB/Rel transcription factors in B cells, and NF-κB/Rel complexes can inhibit cell apoptosis, we investigated whether the antiapoptotic effect of G28-5, in our system, could be related to modulation of NF-κB/Rel activity. As expected, B-CLL cells displayed significant levels of nuclear NF-κB/Rel activity; p50, RelA, and c-Rel components of the NF-κB/Rel protein family were identified in these complexes. After exposure to fludarabine, NF-κB/Rel complexes were decreased in the nuclei. The addition of G28-5 upregulated the NF-κB/Rel levels. To determine the involvement of NF-κB/Rel activity in the G28-5–mediated inhibition of apoptosis, we blocked the transcription factor with a decoy oligonucleotide, corresponding to the NF-κB/Rel consensus sequence. Cells incubated with the anti-CD40 MoAb in the presence of the decoy oligonucleotide but not a control oligonucleotide displayed a complete impairment of the G28-5 antiapoptotic effect, indicating that NF-κB/Rel activity was required for the inhibition of apoptosis. These results suggest that CD40 triggering in vivo could counteract the apoptotic effect of fludarabine on B-CLL cells and that its neutralization, or the use of NF-κB/Rel inhibitors, could improve the therapeutic effect of fludarabine. © 1998 by The American Society of Hematology.

Induction of Estrogen Receptor α Expression with Decoy Oligonucleotide Targeted to NFATc1 Binding Sites in Osteoblasts

2007 ◽  
Vol 71 (6) ◽  
pp. 1457-1462 ◽  
Author(s):  
Letizia Penolazzi ◽  
Margherita Zennaro ◽  
Elisabetta Lambertini ◽  
Elisa Tavanti ◽  
Elena Torreggiani ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Binding Sites ◽  
Estrogen Receptor Α ◽  
Decoy Oligonucleotide
Sign in / Sign up

Export Citation Format

Share Document